|
T900607 in Treating Patients With Unresectable Liver Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on T900607 in Treating Patients With Unresectable Liver Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. T900607 in Treating Patients With Unresectable Liver Cancer Clinical research trials and T900607 in Treating Patients With Unresectable Liver Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including T900607 in Treating Patients With Unresectable Liver Cancer. T900607 in Treating Patients With Unresectable Liver Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a T900607 in Treating Patients With Unresectable Liver Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their T900607 in Treating Patients With Unresectable Liver Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > T900607 in Treating Patients With Unresectable Liver Cancer  T900607 in Treating Patients With Unresectable Liver Cancer
T900607 in Treating Patients With Unresectable Liver Cancer
For Condition: advanced adult primary liver cancer,localized unresectable adult primary liver cancer,adult primary hepatocellular carcinoma
Status: No longer recruiting
Sponsor(s): Ireland Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable liver cancer.
Details: OBJECTIVES: - Determine the complete and partial response rates of patients with chemotherapy-naïve unresectable hepatocellular carcinoma treated with T900607. - Determine the efficacy of this drug, in terms of duration of response and time to disease progression, in these patients. - Determine the pharmacokinetics of this drug in these patients. - Determine the safety profile of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed unresectable hepatocellular carcinoma (HCC) - Bidimensionally measurable disease defined as at least 1 lesion that is 1 cm or more in 2 dimensions by CT scan - Class A or B Child-Pugh liver classification - No prior CNS metastases or carcinomatous meningitis PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count at least 1,500/mm^3* - Platelet count at least 100,000/mm^3* - Hemoglobin at least 8.5 g/dL* NOTE: *More than 7 days since prior blood transfusions or growth factors Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - Albumin greater than 2.5 g/dL - AST and ALT no greater than 3 times ULN - INR no greater than 1.5 (unless receiving anticoagulants) Renal - Creatinine no greater than 2 times ULN Cardiovascular - LVEF at least 50% - No New York Heart Association class III or IV cardiac disease - No acute anginal symptoms Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study - No severe concurrent disease, infection, or co-morbidity that would preclude study entry - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - No prior immunotherapy for HCC - No concurrent therapeutic biological response modifier Chemotherapy - No prior chemotherapy for HCC - No prior chemoembolization for HCC - No other concurrent cytotoxic chemotherapy Endocrine therapy - At least 6 weeks since prior hormonal therapy (an indicator lesion must exist outside the area of therapy - No concurrent hormonal anticancer therapy Radiotherapy - No prior radiotherapy for HCC - At least 6 weeks since prior radiofrequency ablation, selective internal radiation, or embolization (an indicator lesion must exist outside the area of therapy) - No concurrent radiotherapy (including palliative therapy) Surgery - At least 6 weeks since prior surgical resection (an indicator lesion must exist outside the area of therapy) - Recurrence at the margin of the surgical resection is allowed - At least 6 weeks since prior cryosurgery - More than 4 weeks since other prior major surgery Other - More than 4 weeks since prior investigational therapy - At least 6 weeks since prior intratumoral ethanol injection (an indicator lesion must exist outside the area of therapy) - No other concurrent investigational anticancer therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JoannaBrell, Study Chair, Ireland Cancer Center
Ireland Cancer Center
Cleveland, Ohio, 44106-1714
United States
Additional Information:
Study ID Numbers: CDR0000270198; TULA-TULI-2202,TULA-T-607-004,CWRU-100211
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054262
Other Advanced Adult Primary Liver Cancer Studies:
1. Epirubicin and Thalidomide in Treating Patients With Liver Cancer
2. Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
3. Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
4. T900607 in Treating Patients With Unresectable Liver Cancer
5. DX-8951f in Treating Patients With Liver Cancer
Related Studies:
Other advanced adult primary liver cancer Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
T900607 in Treating Patients With Unresectable Liver Cancer
|
|
|
|
|
|
|
|
